<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nmp</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Sklifosovsky Journal "Emergency Medical Care"</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2223-9022</issn><issn pub-type="epub">2541-8017</issn><publisher><publisher-name>“N.V. Sklifosovsky Research Institute for Emergency Medicine”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23934/2223-9022-2019-8-2-160-165</article-id><article-id custom-type="elpub" pub-id-type="custom">nmp-634</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Трансплантация фекальной микробиоты: прошлое, настоящее и будущее</article-title><trans-title-group xml:lang="en"><trans-title>Fecal Microbiota Transplantation: Past, Present and Future</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7473-8727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евдокимова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yevdokimova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евдокимова Наталья Витальевна - кандидат биологических наук, старший научный сотрудник лаборатории клинической микробиологии.</p><p>129090, Москва, Б. Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Natalya Vitalyevna Yevdokimova - Cand. Biol. Sci., Senior Researher of the Laboratory of Clinical Microbiology.</p><p>3 Bolshaya Sukharevskaya Square, Moscow 129090</p></bio><email xlink:type="simple">env1111@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6167-7117</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черненькая</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chyornenkaya</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черненькая Татьяна Витальевна - кандидат медицинских наук, заведующая лабораторией клинической микробиологии.</p><p>129090, Москва, Б. Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Tatyana Vitalyevna Chyornenkaya - Cand. Med. Sci., Head of the Laboratory of Clinical Microbiology.</p><p>3 Bolshaya Sukharevskaya Square, Moscow 129090</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. Москвы»<country>Россия</country></aff><aff xml:lang="en">N.V. Sklifosovsky Research Institute for Emergency Medicine<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>10</day><month>08</month><year>2019</year></pub-date><volume>8</volume><issue>2</issue><fpage>160</fpage><lpage>165</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Евдокимова Н.В., Черненькая Т.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Евдокимова Н.В., Черненькая Т.В.</copyright-holder><copyright-holder xml:lang="en">Yevdokimova N.V., Chyornenkaya T.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jnmp.ru/jour/article/view/634">https://www.jnmp.ru/jour/article/view/634</self-uri><abstract><p>В обзоре обобщены последние данные о результатах применения, показаниях для назначения и способах проведения фекальной микробной трансплантации (FMT), а также рассмотрены перспективы использования и терапевтического потенциала FMT. В последние годы FMT вызывает огромный интерес, особенно в связи с резким ростом числа Clostridium difficile-ассоциированных инфекций (CDI). В настоящее время FMT рекомендована в качестве альтернативного метода лечения рецидивирующей CDI, в случае, когда стандартная антимикробная терапия неэффективна. FMT представляет собой введение в кишечник пациента суспендированного биоматериала от здорового донора. Точный механизм того, что происходит при FMT, не совсем ясен, однако предполагается, что таким образом восстанавливается состав и функции микрофлоры кишечника больного. На эффективность FMT влияют способ введения, качество трансплантируемого материала, его количество, а также все лечебные мероприятия, проведенные ранее.</p></abstract><trans-abstract xml:lang="en"><p>In this review, we have summarized the latest evidence, indications, and methods of fecal microbiota transplantation (FMT), and analyzed the prospects and therapeutic potentials of this procedure. In recent years, FMT has attracted great interest, especially due to the global Clostridium difficile infection (CDI). FMT is now recommended as alternative therapy for recurrent CDI when standard treatment with antibiotics fails. It involves putting suspended biomaterial with intestinal microorganisms of a healthy donor into the intestine of a patient. Although the exact mechanism of action is not entirely clear, it is believed to restore the composition and function of the intestinal microbiota in diseased patients. The efficacy varies depending on the route of administration, quality and volume of donor biomaterial, and treatment before the procedure.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фекальная микробиомная трансплантация</kwd><kwd>альтернативная терапия</kwd><kwd>хроническая Clostridium difficile-ассоциированная инфекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>fecal microbiota transplantation</kwd><kwd>alternative therapy</kwd><kwd>recurrent Clostridium difficile infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Colman R.J., Rubin D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J Crohns Colitis. 2014; 8(12): 1569-1581. PMID: 25223604PMCID. DOI: 10.1016/j.crohns.2014.08.006.</mixed-citation><mixed-citation xml:lang="en">Colman R.J., Rubin D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J Crohns Colitis. 2014; 8(12): 1569-1581. PMID: 25223604. PMCID. DOI: 10.1016/j.crohns.2014.08.006.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Smits L.P., Bouter K.E., de Vos W.M., et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013; 145 (5): 946-953. PMID: 24018052. DOI:10.1053/j.gastro.2013.08.058.</mixed-citation><mixed-citation xml:lang="en">Smits L.P., Bouter K.E., de Vos W.M., et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013; 145(5): 946-953. PMID: 24018052. DOI: 10.1053/j.gastro.2013.08.058</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lessa F.C., Mu Y., Bamberg W.M., et al. Burden of Clostridium difficile infection in the United States. Engl J Med. 2015; 372(9): 825-834. PMID: 25714160. DOI: 10.1056/NEJMoa1408913.</mixed-citation><mixed-citation xml:lang="en">Lessa F.C., Mu Y., Bamberg W.M., et al. Burden of Clostridium difficile infection in the United States. Engl J Med. 2015; 372(9): 825-834. PMID: 25714160. DOI: 10.1056/NEJMoa1408913.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin T.A., Gessert C.E., Aas J., Bakken J.S. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013; (19): 22-26. PMID: 23182843. DOI: 10.1016/j.anaerobe.2012.11.004.</mixed-citation><mixed-citation xml:lang="en">Rubin T.A., Gessert C.E., Aas J., Bakken J.S. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013; (19): 22-26. PMID: 23182843. DOI: 10.1016/j.anaerobe.2012.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5): 407-415. PMID: 23323867. DOI: 10.1056/NEJMoa1205037.</mixed-citation><mixed-citation xml:lang="en">Van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5): 407-415. PMID: 23323867. DOI: 10.1056/NEJMoa1205037.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010; 44(5): 354-360. PMID: 20048681. DOI: 10.1097/MCG.0b013e3181c87e02.</mixed-citation><mixed-citation xml:lang="en">Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010; 44(5): 354-360. PMID: 20048681. DOI: 10.1097/MCG.0b013e3181c87e02.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Song Y., Garg S., Girotra M., et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One. 2013; 8 (11): e81330. PMID: 24303043. DOI: 10.1371/journal.pone.0081330.</mixed-citation><mixed-citation xml:lang="en">Song Y., Garg S., Girotra M., et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One. 2013; 8 (11): e81330. PMID: 24303043. DOI: 10.1371/journal.pone.0081330.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jalanka J., Mattila E., Jouhten H., et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016; 14(1): 155. PMID: 27724956. DOI: 10.1186/s12916-016-0698-z.</mixed-citation><mixed-citation xml:lang="en">Jalanka J., Mattila E., Jouhten H., et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016; 14(1): 155. PMID: 27724956. DOI: 10.1186/s12916-016-0698-z.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23): 2442-2449. PMID: 16322602. DOI: 10.1056/NEJMoa051639.</mixed-citation><mixed-citation xml:lang="en">Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23): 2442-2449. PMID: 16322602. DOI: 10.1056/NEJMoa051639.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5): 422-431. PMID: 21288078. DOI: 10.1056/NEJMoa0910812.</mixed-citation><mixed-citation xml:lang="en">Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5): 422-431. PMID: 21288078. DOI: 10.1056/NEJMoa0910812.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. URL: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf (Accessed 28 May 2019).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009; 58(6): 403-410. PMID: 19394704. DOI: 10.1016/j.jinf.2009.03.010.</mixed-citation><mixed-citation xml:lang="en">Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009; 58(6): 403-410. PMID: 19394704. DOI: 10.1016/j.jinf.2009.03.010.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Surawicz C.M., Mcfarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000; 31(4): 1012-1017. PMID: 11049785. DOI: 10.1086/318130.</mixed-citation><mixed-citation xml:lang="en">Surawicz C.M., Mcfarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000; 31(4): 1012-1017. PMID: 11049785. DOI: 10.1086/318130.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McFarlandL.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97 (7): 1769-1775. PMID: 12135033. DOI: 10.1111/j.1572-0241.2002.05839.x.</mixed-citation><mixed-citation xml:lang="en">McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7): 1769-1775. PMID: 12135033. DOI: 10.1111/j.1572-0241.2002.05839.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cornely O.A., Miller M.A., Louie T.J., et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55 Suppl 2: S154-61. PMID: 22752865. DOI: 10.1093/cid/cis462.</mixed-citation><mixed-citation xml:lang="en">Cornely O.A., Miller M.A., Louie T.J., et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55 Suppl 2: S154-161. PMID: 22752865. DOI: 10.1093/cid/cis462.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gerding D.N., Muto C.A., Owens R.C. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008; 46(Suppl 1): S43-49. PMID: 1817722. DOI: 10.1086/521861.</mixed-citation><mixed-citation xml:lang="en">Gerding D.N., Muto C.A., Owens R.C. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008; 46(Suppl 1): S43-49. PMID: 1817722. DOI: 10.1086/521861.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson K.H. The microecology of Clostridium difficile. Clin Infect Dis. 1993; 16 (Suppl 4): S214-8. PMID: 8324122.</mixed-citation><mixed-citation xml:lang="en">Wilson K.H. The microecology of Clostridium difficile. Clin Infect Dis. 1993; 16(Suppl 4): S214-218. PMID: 8324122.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cammarota G., Ianiro G., Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014; 48(8): 693-702. PMID: 24440934. DOI: 10.1097/MCG.0000000000000046.</mixed-citation><mixed-citation xml:lang="en">Cammarota G., Ianiro G., Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014; 48(8):693-702. PMID: 24440934. DOI: 10.1097/MCG.0000000000000046.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium Difficile Infection Not Responsive to Standard Therapies. US Government DoHaHS, Food and Drug, Administration, Center for Biologics Evaluation and Research. Jul. 2013. URL: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatorylnformation/Guidances/Vaccines/ucm361379.htm</mixed-citation><mixed-citation xml:lang="en">Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium Difficile Infection Not Responsive to Standard Therapies. US Government DoHaHS, Food and Drug, Administration, Center for Biologics Evaluation and Research. Jul 2013. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatorylnformation/Guidances/Vaccines/ucm361379.htm (Accessed 28 May 2019).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cammarota G., Ianiro G., Tilg H., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66 (4): 569-580. PMID: 28087657. DOI: 10.1136/gutjnl-2016-313017.</mixed-citation><mixed-citation xml:lang="en">Cammarota G., Ianiro G., Tilg H., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66(4): 569-580. PMID: 28087657. DOI: 10.1136/gutjnl-2016-313017.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cammarota G., Masucci L., Ianiro G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 41(9): 835-843. PMID: 2572880. DOI: 10.1111/apt.13144.</mixed-citation><mixed-citation xml:lang="en">Cammarota G., Masucci L., Ianiro G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 41(9): 835-843. PMID: 2572880. DOI: 10.1111/apt.13144.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lee C.H., Steiner T., Petrof E.O., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016; 315(2): 142-149. PMID: 26757463. DOI: 10.1001/jama.2015.18098.</mixed-citation><mixed-citation xml:lang="en">Lee C.H., Steiner T., Petrof E.O., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016; 315(2): 142-149. PMID: 26757463. DOI: 10.1001/jama.2015.18098.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cammarota G., Ianiro G., Magalini S., et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015; 163(6): 487-488. PMID: 26370022. DOI: 10.7326/L15-5139.</mixed-citation><mixed-citation xml:lang="en">Cammarota G., Ianiro G., Magalini S., et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015; 163(6): 487-488. PMID: 26370022. DOI: 10.7326/L15-5139.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer M., Sipe B.W., Rogers N.A., et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015; 42(4): 470-476. PMID: 26096320. DOI: 10.1111/apt.13290.</mixed-citation><mixed-citation xml:lang="en">Fischer M., Sipe B.W., Rogers N.A., et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015; 42(4): 470-476. PMID: 26096320. DOI: 10.1111/apt.13290.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Weingarden A.R., Hamilton M.J., Sadowsky M.J., Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013; 47(8): 735-737. PMID: 23632358. DOI: 10.1097/MCG.0b013e31829004ae.</mixed-citation><mixed-citation xml:lang="en">Weingarden A.R., Hamilton M.J., Sadowsky M.J., Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013; 47(8): 735-737. PMID: 23632358. DOI: 10.1097/MCG.0b013e31829004ae.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Satokari R., Mattila E., Kainulainen V., Arkkila P.E. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficileinfection—an observational cohort study. Aliment Pharmacol Ther. 2015; 41(1): 46-53. PMID: 25355279. DOI: 10.1111/apt.13009.</mixed-citation><mixed-citation xml:lang="en">Satokari R., Mattila E., Kainulainen V., Arkkila P.E. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficileinfection—an observational cohort study. Aliment Pharmacol Ther. 2015; 41(1): 46-53. PMID: 25355279. DOI: 10.1111/apt.13009.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Browne H.P., Forster S.C., Anonye B.O., et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature. 2016; 533(7604): 543-546. MID: 27144353. DOI: 10.1038/nature17645.</mixed-citation><mixed-citation xml:lang="en">Browne H.P., Forster S.C., Anonye B.O., et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature. 2016; 533(7604): 543-546. MID: 27144353. DOI: 10.1038/nature17645.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Drekonja D., Reich J., Gezahegn S., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015; 162(9): 630-638. PMID: 25938992. DOI: 10.7326/M14-2693.</mixed-citation><mixed-citation xml:lang="en">Drekonja D., Reich J., Gezahegn S., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015; 162(9): 630-638. PMID: 25938992. DOI: 10.7326/M14-2693.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Frank J., Hogenauer C., Grochenig H.P., et al. Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatment [abstract]. J Crohns Colitis. 2015; 9: S245.</mixed-citation><mixed-citation xml:lang="en">Frank J., Hogenauer C., Grochenig H.P., et al. Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatment [abstract]. J Crohns Colitis. 2015; 9: S245.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Baxter M., Ahmad T., Colville A., Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis. 2015; 61(1): 136-137. PMID: 25805303. DOI: 10.1093/cid/civ247.</mixed-citation><mixed-citation xml:lang="en">Baxter M., Ahmad T., Colville A., Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis. 2015; 61(1): 136-137. PMID: 25805303. DOI: 10.1093/cid/civ247.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer M., Kao D., Mehta S.R., et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016; 111(7): 10241031. PMID: 27185076. DOI: 10.1038/ajg.2016.180.</mixed-citation><mixed-citation xml:lang="en">Fischer M., Kao D., Mehta S.R., et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016; 111(7): 10241031. PMID: 27185076. DOI: 10.1038/ajg.2016.180.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Moayyedi P., Surette M.G., Kim P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterol. 2015; 149(1): 102-109. PMID: 25857665. DOI: 10.1053/j.gastro.2015.04.001.</mixed-citation><mixed-citation xml:lang="en">Moayyedi P., Surette M.G., Kim P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterol. 2015; 149(1): 102-109. PMID: 25857665. DOI: 10.1053/j.gastro.2015.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Holvoet T., Joossens M., Wang J., et al. Assessment of faecal microbial transfer inirritable bowel syndrome with severe bloating. Gut. 2017; 66 (5): 980-982. PMID: 27511198. DOI: 10.1136/gutjnl-2016-312513.</mixed-citation><mixed-citation xml:lang="en">Holvoet T., Joossens M., Wang J., et al. Assessment of faecal microbial transfer inirritable bowel syndrome with severe bloating. Gut. 2017; 66(5): 980-982. PMID: 27511198. DOI: 10.1136/gutjnl-2016-312513.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kakihana K., Fujioka Y., Suda W., et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. Blood.2016; 128(16): 2083-2088. PMID: 27461930. DOI: 10.1182/blood-2016-05-717652.</mixed-citation><mixed-citation xml:lang="en">Kakihana K., Fujioka Y., Suda W., et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. Blood. 2016; 128(16): 2083-2088. PMID: 27461930. DOI: 10.1182/blood-2016-05-717652.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
